This probiotic combination shows promise as a preventive and therapeutic agent for oral health, especially in mitigating pathogenic bacterial growth and reducing inflammation in periodontal disease.

Animal model experiments show that a mixture of LA85 and BLa80 can alleviate the inflammation caused by H. pylori infection. The combination of these strains proves more effective in relieving inflammation than either strain alone.

This probiotic patent focuses on a dual-strain formulation targeting osteoporosis improvement. The formulation contains Limosilactobacillus reuteri LR38 and Lacticaseibacillus rhamnosus LRa05, which together exhibit synergistic effects on bone health by mitigating bone density loss and decreasing osteoclastogenic factors.

This patent discusses a probiotic agent aimed at improving hypertension, composed primarily of the Akkermansia muciniphila Akk11 and Lacticaseibacillus rhamnosus LRa05.

This probiotic composition, containing Akkermansia muciniphila Akk11 and Lactobacillus johnsonii LJ09, offers a novel and safe approach to managing hyperuricemia. Its synergistic action not only regulates uric acid levels but also protects the kidneys, reducing the risk of complications associated with high uric acid.

The synergy between WecStrainTM Bifidobacterium longum subsp. longum BL11 and WecStrainTM Lacticaseibacillus casei LC89 offers a novel, safe approach for managing mental health disorders through gut microbiota modulation.